Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea

References

• Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900–1901. doi:10.1001/jama.291.15.1900
   PubMedGoogle Scholar
• Resnikoff S, Pascolini D, Etya’Ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
   PubMed Web of Science ®Google Scholar
• Rozing MP, Durhuus JA, Nielsen MK, et al. Age-related macular degeneration: a two-level model hypothesis. Prog Retin Eye Res. 2019;76:100825.
   PubMed Web of Science ®Google Scholar
• García-Layana A, García-Arumí J, Figueroa M, Arias Barquet L, Ruíz-Moreno J, Monclús-Arbona L. Management of wet age-related macular degeneration in Spain: challenges for treat and extend implementation in routine clinical practice. J Ophthalmol. 2019;2019:1–10. doi:10.1155/2019/9821509
   Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):P1–P65.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Group CR. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F. Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PLoS One. 2015;10(7):e0133968. doi:10.1371/journal.pone.0133968
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Liu Y, Yeh W-S, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157(4):825–833. e821. doi:10.1016/j.ajo.2013.12.018
   Web of Science ®Google Scholar
• Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther. 2013;30(12):1111–1127. doi:10.1007/s12325-013-0078-4
   Web of Science ®Google Scholar
• Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15–22. e12. doi:10.1016/j.ajo.2007.03.047
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117(11):1503–1510. doi:10.1001/archopht.117.11.1503
   PubMedGoogle Scholar
• Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121(10):1392–1396. doi:10.1001/archopht.121.10.1392
   PubMedGoogle Scholar
• Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):625–629. doi:10.1007/s00417-003-0667-z
   PubMed Web of Science ®Google Scholar
• Byeon SH, Lee SC, Oh H-S, Kim SS, Koh HJ, Kwon OW. Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. Jpn J Ophthalmol. 2008;52(1):57–62. doi:10.1007/s10384-007-0498-2
   PubMed Web of Science ®Google Scholar
• Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1):19–29. doi:10.1016/j.preteyeres.2009.10.001
   PubMed Web of Science ®Google Scholar
• Lim LS, Cheung CMG, Wong TY. Asian age-related macular degeneration: current concepts and gaps in knowledge. Asia Pac J Ophthalmol. 2013;2(1):32–41. doi:10.1097/APO.0b013e31827ff5bc
   Google Scholar
• Yannuzzi LA, Negrão S, Tomohiro I, et al. Retinal angiomatous proliferation in age–related macular degeneration. Retina. 2012;32:416–434. doi:10.1097/IAE.0b013e31823f9b3b
   Google Scholar
• Chang W, Noh DH, Sagong M, Kim IT. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Mol Vis. 2013;19:702.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci. 2002;99(17):11393–11398. doi:10.1073/pnas.172398299
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–668. doi:10.1136/bjo.2007.134874
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee DW, Chang YS, Kim JW, Kim CG. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2016;254(11):2101–2109. doi:10.1007/s00417-016-3353-7
   Web of Science ®Google Scholar
• Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652–660. e651. doi:10.1016/j.ajo.2013.05.038
   Web of Science ®Google Scholar
• Shin JY, Yu HG. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina. 2014;34(12):2359–2366. doi:10.1097/IAE.0000000000000225
   Web of Science ®Google Scholar
• Ogura Y, Terasaki H, Gomi F, et al. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99(1):92–97.
   Web of Science ®Google Scholar
• Lee FL, Kwon OW, Chung H, Lai CC, Sheu SJ, Yoon YH. Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study. Acta Ophthalmol. 2012;90(5):e406–407. doi:10.1111/j.1755-3768.2011.02262.x
   Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Monés J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243(1):1–8. doi:10.1159/000502747
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti–vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2(7):645–653. doi:10.1016/j.oret.2018.01.006
   PubMedGoogle Scholar
• Weber M, Velasque L, Coscas F, Faure C, Aubry I, Cohen SY. Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study. BMJ Open Ophthalmol. 2019;4(1):e000109. doi:10.1136/bmjophth-2017-000109
   PubMed Web of Science ®Google Scholar
• Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2016;123(12):2545–2553. doi:10.1016/j.ophtha.2016.08.016
   PubMed Web of Science ®Google Scholar
• Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2017;174:160–168. doi:10.1016/j.ajo.2016.09.038
   PubMed Web of Science ®Google Scholar
• Framme C, Eter N, Hamacher T, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina. 2018;2(6):539–549. doi:10.1016/j.oret.2017.09.017
   Google Scholar
• Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye. 2017;31(12):1697–1706. doi:10.1038/eye.2017.143
   PubMed Web of Science ®Google Scholar
• Providência J, Rodrigues TM, Oliveira M, et al. Real-world results of aflibercept versus ranibizumab for the treatment of exudative AMD using a fixed regimen. Biomed Res Int. 2018;2018:1–7. doi:10.1155/2018/9276580
   Web of Science ®Google Scholar
• Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153(4):678–686. e672. doi:10.1016/j.ajo.2011.09.013
   Web of Science ®Google Scholar
• Arpa C, Khalid H, Chandra S, et al. Ten-year survival trends of neovascular age-related macular degeneration at first presentation. Br J Ophthalmol. 2020. doi:10.1136/bjophthalmol-2020-317161
   Web of Science ®Google Scholar
• Bloch SB, la Cour M, Sander B, et al. Predictors of 1‐year visual outcome in neovascular age‐related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013;91(1):42–47. doi:10.1111/j.1755-3768.2011.02268.x
   Web of Science ®Google Scholar
• Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina (Philadelphia, Pa). 2020;40(9):1673. doi:10.1097/IAE.0000000000002670
   PubMed Web of Science ®Google Scholar
• Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):474–481. doi:10.1097/IAE.0b013e31827b6324
   PubMed Web of Science ®Google Scholar
• Menon G, Chandran M, Sivaprasad S, Chavan R, Narendran N, Yang Y. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab?(BeMOc Trial). Eye. 2013;27(8):959–963. doi:10.1038/eye.2013.93
   PubMed Web of Science ®Google Scholar
• Hatz K, Prünte C, Bloch SB, la Cour M, Sander B. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):188–194. doi:10.1136/bjophthalmol-2013-303444
   Web of Science ®Google Scholar
• Moorthy RS, Lyon AT, Rabb MF, Spaide RF, Yannuzzi LA, Jampol LM. Idiopathic polypoidal choroidal vasculopathy of the macula. Ophthalmology. 1998;105(8):1380–1385. doi:10.1016/S0161-6420(98)98016-2
   Web of Science ®Google Scholar
• Ying G-S, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122–129. doi:10.1016/j.ophtha.2012.07.042
   PubMed Web of Science ®Google Scholar
• Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1237–1245. doi:10.1016/j.ophtha.2013.12.029
   PubMed Web of Science ®Google Scholar
• Suzuki M, Nagai N, Izumi-Nagai K, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98(9):1186–1191. doi:10.1136/bjophthalmol-2013-304670
   Web of Science ®Google Scholar
• Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1014–1023. e1012. doi:10.1016/j.ajo.2015.07.034
   Web of Science ®Google Scholar
• Schwartz R, Loewenstein A. Early detection of age related macular degeneration: current status. Int J Retina Vitreous. 2015;1(1):1–8. doi:10.1186/s40942-015-0022-7
   Google Scholar